| Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination GG Zhanel, CD Lawson, H Adam, F Schweizer, S Zelenitsky, ... Drugs 73, 159-177, 2013 | 489 | 2013 |
| Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations GG Zhanel, CK Lawrence, H Adam, F Schweizer, S Zelenitsky, M Zhanel, ... Drugs 78, 65-98, 2018 | 375 | 2018 |
| Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006 GG Zhanel, M DeCorby, N Laing, B Weshnoweski, R Vashisht, F Tailor, ... Antimicrobial agents and chemotherapy 52 (4), 1430-1437, 2008 | 370 | 2008 |
| Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli GG Zhanel, P Chung, H Adam, S Zelenitsky, A Denisuik, F Schweizer, ... Drugs 74, 31-51, 2014 | 364 | 2014 |
| New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin GG Zhanel, D Calic, F Schweizer, S Zelenitsky, H Adam, ... Drugs 70, 859-886, 2010 | 362 | 2010 |
| Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli GG Zhanel, AR Golden, S Zelenitsky, K Wiebe, CK Lawrence, HJ Adam, ... Drugs 79, 271-289, 2019 | 338 | 2019 |
| Review of eravacycline, a novel fluorocycline antibacterial agent GG Zhanel, D Cheung, H Adam, S Zelenitsky, A Golden, F Schweizer, ... Drugs 76, 567-588, 2016 | 245 | 2016 |
| Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008) GG Zhanel, M DeCorby, H Adam, MR Mulvey, M McCracken, ... Antimicrobial agents and Chemotherapy 54 (11), 4684-4693, 2010 | 235 | 2010 |
| Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of gram-negative bacterial infectionsinfections P Lagacé-Wiens, A Walkty, JA Karlowsky Core evidence, 13-25, 2014 | 219 | 2014 |
| Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization–time of flight mass spectrometry and a … PRS Lagacé-Wiens, HJ Adam, JA Karlowsky, KA Nichol, PF Pang, ... Journal of clinical microbiology 50 (10), 3324-3328, 2012 | 216 | 2012 |
| Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens GG Zhanel, R Love, H Adam, A Golden, S Zelenitsky, F Schweizer, ... Drugs 75, 253-270, 2015 | 207 | 2015 |
| Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase-and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian … AJ Denisuik, PRS Lagacé-Wiens, JD Pitout, MR Mulvey, PJ Simner, ... Journal of Antimicrobial Chemotherapy 68 (suppl_1), i57-i65, 2013 | 192 | 2013 |
| Ceftaroline: A Novel Broad-Spectrum Cephalosporin with Activity against Meticillin-Resistant Staphylococcus aureus GG Zhanel, G Sniezek, F Schweizer, S Zelenitsky, PRS Lagacé-Wiens, ... Drugs 69, 809-831, 2009 | 185 | 2009 |
| Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study JA Karlowsky, PRS Lagacé-Wiens, PJ Simner, MR DeCorby, HJ Adam, ... Antimicrobial agents and chemotherapy 55 (7), 3169-3175, 2011 | 183 | 2011 |
| Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study GG Zhanel, HJ Adam, MR Baxter, J Fuller, KA Nichol, AJ Denisuik, ... Journal of Antimicrobial Chemotherapy 68 (suppl_1), i7-i22, 2013 | 177 | 2013 |
| In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the … A Walkty, H Adam, M Baxter, A Denisuik, P Lagace-Wiens, JA Karlowsky, ... Antimicrobial agents and chemotherapy 58 (5), 2554-2563, 2014 | 148 | 2014 |
| Adverse reactions to β-lactam antimicrobials P Lagacé-Wiens, E Rubinstein Expert opinion on drug safety 11 (3), 381-399, 2012 | 143 | 2012 |
| Influenza epidemiology—past, present, and future PRS Lagace-Wiens, E Rubinstein, A Gumel Critical care medicine 38, e1-e9, 2010 | 129 | 2010 |
| Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β … PRS Lagacé-Wiens, F Tailor, P Simner, M DeCorby, JA Karlowsky, ... Antimicrobial agents and chemotherapy 55 (5), 2434-2437, 2011 | 120* | 2011 |
| Prevalence and characterization of extended-spectrum β-lactamase–and AmpC β-lactamase–producing Escherichia coli: results of the CANWARD 2007–2009 study PJ Simner, GG Zhanel, J Pitout, F Tailor, M McCracken, MR Mulvey, ... Diagnostic microbiology and infectious disease 69 (3), 326-334, 2011 | 99 | 2011 |
Michael MulveyNational Microbiology LaboratoryAdresse e-mail validée de phac-aspc.gc.ca
